Explore the words cloud of the CannaPreg project. It provides you a very rough idea of what is the project "CannaPreg" about.
The following table provides information about the project.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
|Coordinator Country||France [FR]|
|Total cost||150˙000 €|
|EC max contribution||150˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2015-01-01 to 2016-06-30|
Take a look of project's partnership.
|1||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||coordinator||150˙000.00|
Excessive activation of the cannabinoid type-1 receptor (CB1) in the brain by synthetic, endogenous or plant-derived (cannabis sativa) cannabinoids can lead to pathological states, which could be ameliorated by blocking receptor signalling. However, due to the large number of functions involving the CB1 receptor, direct CB1 antagonist drugs induce side effects limiting their therapeutic use. During the ERC-StG funded project, we found that a particular endogenous and labile lipid compound, pregnenolone, acts as an allosteric and signal-specific inhibitor of CB1 receptors in the brain. Thus, stable pregnenolone-derivative drugs have been produced to exploit the therapeutic potential of allosteric inhibition of CB1 receptor signalling, which can be used to decrease pathological over-activation of CB1 receptors. One clear pathological state where over-activation of CB1 receptors plays a key role is schizophrenia and psychotic syndromes. Indeed, cannabis and synthetic cannabinoids can induce psychotic states and excessive CB1 receptor signalling has been proposed to participate in the etiopathogenesis of human schizophrenia. Thus, the present project aims at establishing the innovative and commercial potential of this new class of drugs, stable derivatives of pregnenolone, as allosteric inhibitors of the CB1 receptor for the treatment of psychotic syndromes. The following issues will be addressed: 1. Technical activities will identify the compounds with the best therapeutic potential. 2. Market studies will determine the potential competitiveness of these compounds. 3. Additional industry partnerships will be sought for later stages of commercial development. By covering these essential steps bridging a scientific idea from basic research to therapeutic applications, the present project is fully integrated in the spirit of the ERC PoC program and, if successful, will provide key medical, economical and societal benefits to Europe.
|year||authors and title||journal||last update|
J.F. Oliveira da Cruz, L.M. Robin, F. Drago, G. Marsicano, M. Metna-Laurent
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse
published pages: 35-42, ISSN: 0306-4522, DOI: 10.1016/j.neuroscience.2015.05.002
Edgar Soria-GÃ³mez, Arnau Busquets-Garcia, Fei Hu, Amine Mehidi, Astrid Cannich, Liza Roux, Ines Louit, Lucille Alonso, Theresa Wiesner, Francois Georges, DaniÃ¨le Verrier, Peggy Vincent, Guillaume Ferreira, Minmin Luo, Giovanni Marsicano
Habenular CB1 Receptors Control the Expression of Aversive Memories
published pages: 306-313, ISSN: 0896-6273, DOI: 10.1016/j.neuron.2015.08.035
Arnau Busquets Garcia, Edgar Soria-Gomez, Luigi Bellocchio, Giovanni Marsicano
Cannabinoid receptor type-1: breaking the dogmas
published pages: 990, ISSN: 2046-1402, DOI: 10.12688/f1000research.8245.1
Ana GutiÃ©rrez-RodrÃguez, Nagore Puente, Izaskun Elezgarai, Sabine Ruehle, Beat Lutz, Leire Reguero, Inmaculada Gerrikagoitia, Giovanni Marsicano, Pedro Grandes
Anatomical characterization of the cannabinoid CB 1 receptor in cell-type-specific mutant mouse rescue models
published pages: , ISSN: 0021-9967, DOI: 10.1002/cne.24066
|Journal of Comparative Neurology||2019-07-23|
Beat Lutz, Giovanni Marsicano, Rafael Maldonado, Cecilia J. Hillard
The endocannabinoid system in guarding against fear, anxiety and stress
published pages: 705-718, ISSN: 1471-003X, DOI: 10.1038/nrn4036
|Nature Reviews Neuroscience 16/12||2019-07-23|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANNAPREG" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CANNAPREG" are provided by the European Opendata Portal: CORDIS opendata.